Limitations in Treatment of Metastatic Renal Cell Carcinoma
Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.
EP: 1.Overview of Advanced RCC and Diagnosis
EP: 2.First-Line Treatment Strategies in Renal Cell Carcinoma
EP: 3.Limitations in Treatment of Metastatic Renal Cell Carcinoma
EP: 4.CheckMate 9ER Trial Updates
EP: 5.CheckMate 9ER: Quality of Life Data and Treatment Implications in Advanced RCC
EP: 6.Triplet Regimens for First-Line Advanced Renal Cell Carcinoma
EP: 7.Clinical Considerations and Treatment Sequencing for Patients with Advanced RCC
EP: 8.Evolving Treatment Landscape in Advanced Renal Cell Carcinoma
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
November 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
Read More
Understanding Clonal Hematopoiesis in Kidney Cancer Could Improve Cardiovascular Outcomes
November 11th 2023In a presentation at the 2023 International Kidney Cancer Symposium, Maxine Sun, PhD, MPH, discussed the relationship between clonal hematopoiesis in patients with kidney cancer and their risk for cardiac events.
Read More
